Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327040 | 0.98 | HCAR2 (0.47) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| SCHEMBL16247075 | 0.98 | HCAR2 (0.47) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| Hydrochloric Acid SCHEMBL17398190 | 0.96 | HCAR2 (0.46) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| SCHEMBL1269829 | 0.96 | HCAR2 (0.53) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| SCHEMBL56939 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL17107724 | 0.89 | HCAR2 (0.48) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| SCHEMBL12184926 | 0.84 | MKNK1 (0.57) | HCAR2MKNK1MKNK2HCAR3HRH4 | |
| SCHEMBL4016705 | 0.82 | DAO (0.47) | HCAR2DAOMKNK1MKNK2CCNA2 | |
| SCHEMBL31080297 | 0.81 | HCAR2 (0.37) | HCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL17001818 | 0.80 | DRD4 (0.55) | HCAR2MKNK1MKNK2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551482-B2 | Aurora kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545649-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250177393-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025043063-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119053590-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024206628-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023164612-A9 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023164612-A9 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-113493436-B | Amino substituted pyridine derivative and preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| CN-1934113-B | Compositions useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2011-11-09 | — | — | CN | disclosed |
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| CN-1934113-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1716151-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005095406-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
| US-20040116497-A1 | Chromane derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-06-17 | — | — | US | disclosed |
| EP-1379524-A2 | CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002070515-A2 | CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545649-B2 | WDR5-MYC inhibitors | MYC, MYCBP, WDR1 | HCAR2 3268/4885DAO 3370/4885MKNK1 657/4885 |
| US-20250177393-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HCAR2 4842/4885DAO 3881/4885MKNK1 124/4885 |
| US-12551482-B2 | Aurora kinase inhibitors | MYC, AURKA, AURKC | HCAR2 4781/4885DAO 4384/4885MKNK1 65/4885 |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HCAR2 4842/4885DAO 3881/4885MKNK1 124/4885 |
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K1 | HCAR2 4650/4885DAO 3715/4885MKNK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.